News & Resources

The Value That Aggregated Treatment Data Provides to Life Science Companies

The medical and pharmaceutical industries are dependent upon access to large amounts of patient data and utilizing this information in their research and the decisions they make regarding drug development and commercialization. Life science companies must continuously sift through mountains of clinical data. They are challenged with placing these data into their proper context to ensure they are utilized appropriately. With a never-ending flow of information, contextualizing data can be a Herculean task. Many organizations struggle to make sense of the heaps of information they are receiving on an ongoing basis from clinical trials, practicing physician feedback, and clinical advisors.

Curated insight reports from community physicians provide significant value to life science companies; these reports offer a unique window into the minds of healthcare providers. They explore treatment recommendations, provide feedback from clinician experience, and identify patient priorities. However, insight reports often vary in scope and quality.

Aptitude Health’s CASES reports identify key shifts in the healthcare marketplace related to the management of patients with hematologic malignancies and solid tumors. CASES reports help life science companies understand shifts in oncology care and identify education and resource needs. With CASES, you can track changes in clinical decision-making and shifts over time. Read on to learn more about the benefits of these insight reports.

How Can I Choose the Best Insight Reports?
There’s no doubt about it: life science companies offer a wealth of options when it comes to research reports . As you make your decision, look for insight reports that provide depth and breadth. The best insight reports provide a broad look at the current oncology landscape and are provided on an ongoing basis to measure changes over time. By analyzing treatment trends regularly and digging deep into different data points, a well-constructed report can determine the impact of emerging research and help life science companies better understand how they can support the clinical community.

A high-quality insight report offers a better understanding of the therapeutic decision-making process. This information helps guide ongoing clinical trials and drug developments. Remember to look for reports that use aggregated treatment data. This additional feature provides high levels of accuracy and is critical in specialties such as oncology. Consider the following benefits of insight reports that include aggerated data.

Aggregated Data Guide Clinical Decision-Making
Community physicians use the latest data to guide their treatment decisions; in turn, their treatment patterns impact the drug development process. The choices made by physicians help determine the fate of future treatments. As a result, physicians need to stay informed about emerging treatments and industry shifts. Life science companies also need to understand what goes on in the physician’s office.

Because of the global pandemic, outreach and marketing events have been paused. Insight reports help bridge the gap, allowing your company to understand current trends in treatment approaches. A well-constructed report can answer questions about physicians’ approaches and challenges and can provide additional feedback from clinical experts. Insight reports provide a widespread look at physician behavior and track changes over time. They reveal gaps in physicians’ understanding and conflicting priorities. Analyzing these data can positively impact your outreach efforts.

Aggregated Clinical Data Help Shape Drug Development
High-quality clinical data speed up drug development. With aggregated data from community practices, your organization can spot gaps in care within the current marketplace. You can assess whether available treatments have been used to their full potential. In some cases, insight reports may reveal that a new product is unlikely to gain traction or that additional education is needed to understand the value a newly approved therapy can provide . Paying attention to the details these reports can reveal may help your company avoid a failed product launch or proactively address an unmet need.

Keep in mind that aggregated clinical data go well beyond simple numbers. These reports do not just state how many doses of a specific drug were sold or how many patients were treated. Instead, they offer behind-the-scenes insights that can help your company make the smartest decisions possible. Aggregated clinical data found in insight reports place information in context, revealing nationwide and regional trends. These trends can have a significant impact on your company’s future.

Aggregated Data Reveal the Impact of Emerging Research
Insight reports track how clinician behavior shifts over time in regard to treatment approaches and utilization of particular therapeutics or diagnostic tests. Sometimes, you might notice immediately that prescribers’ behavior has not changed in response to new research. That may be a sign that community physicians have not received the educational support they need. Your organization can leverage this information by adjusting marketing and outreach efforts. Sharing relevant treatment data helps physicians provide patients with better care.

Your insight report might reveal other surprising information. For example, prescribers may shun an exciting new drug in favor of an old standby. These unexpected findings offer your company an opportunity to dig deeper. Insight reports point you in the right direction and using aggregated data allows you to better understand clinician priorities.

In-Depth Assessments of HCP Reactions to Data
If you’re looking for the right insight reports in oncology, Aptitude Health can help. Aptitude Health’s reports quickly identify and summarize oncology market dynamics tailored to your needs. They respond to rapid market shifts that impact clinical decision-making.

Each Aptitude Health report offers a rich source of real-world data whether it is focused on expert opinions or care in the community setting. Initial insights are collected from virtual or live roundtable discussions with clinicians who are focused on managing oncology patients with a particular malignancy. These roundtables, led by a key thought leader, may include 10–15 community physicians within the United States if the focus is care in outpatient setting. Discussions focus on specific disease states and analyze the current treatment landscape. Participants also discuss the ongoing impact of new clinical data.

Aptitude Health reports can provide insights into regionally distinct clinical patterns. They show how clinicians diagnose, treat, and respond to conditions within their geographic area. By aggregating many similar events, Aptitude Health provides a clear view of the changes in treatment patterns over time and in different regions.

Aptitude Health’s new service, RECAP, goes beyond a single CASES report. RECAP measures prescriber behavior, using the same set of community oncologists featured in CASES programs on a specific tumor type. RECAP assesses how prescribing habits have, or have not, changed over time within this group of clinicians. RECAP measures prescribing approaches, retention of program content, and challenges and barriers to adoption of therapies by community-based physicians in the US. Reports include a comprehensive data set, key takeaways with expert commentary, and strategic recommendations to help guide education and resource initiatives. RECAP reports allow your organization to zero in on community physicians in your region, providing an on-the-ground look at clinical decision-making and changes in care over time.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.